Carmoterol

Carmoterol

Carmoterol

Chemical compound

Carmoterol (INN;[1] development codes TA-2005 and CHF-4226) is a non-catechol[2] experimental ultra-long-acting β adrenoreceptor agonist (ultra-LABA)[2][3] that was in clinical trials before 2010 when it has been withdrawn from further development based on evidence that the compound does not possess a competitive profile.[4]

Quick Facts Clinical data, Other names ...

Preliminary studies indicated duration of its effect exceeding 24 hours after inhalation of 3 μg.[2] The pharmacologic profile of this medication included the fact its potency in isolated guinea pig trachea is greater than that of formoterol and salmeterol. It is over 100 times more selective for bronchial muscle than myocardial tissue.[5]

References

  1. [1]
    "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 53" (PDF). WHO Drug Information. 19 (1): 74. 2005. Retrieved 25 March 2016.
  2. [2]
    Mario C, Monica K (2008). "27. Bronchodilators: Beta2-Agonists and Anticholingercs". Clinical Asthma. Philadelphia, PA: Mosby / Elsevier Health Sciences. ISBN 978-0-323-04289-5.
  3. [3]
    Cazzola M, Calzetta L, Matera MG (May 2011). "β(2) -adrenoceptor agonists: current and future direction". British Journal of Pharmacology. 163 (1): 4–17. doi:10.1111/j.1476-5381.2011.01216.x. PMC 3085864. PMID 21232045.
  4. [4]
    "Chiesi: Annual Report 2010" (PDF). Chiesi Farmaceutici S.p.A. p. 20. Retrieved 27 March 2016.
  5. [5]
    Donohue JF (2006). "New Options in COPD Therapy". Medscape. Retrieved 27 March 2016.
Stub icon

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Carmoterol, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.